Camrelizumab vs Placebo With Chemotherapy as Neoadjuvant Treatment in Triple-Negative Breast Cancer

Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients with Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial." Related Content: Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer